These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 32726928)

  • 1. Antibodies Inhibiting the Type III Secretion System of Gram-Negative Pathogenic Bacteria.
    Hotinger JA; May AE
    Antibodies (Basel); 2020 Jul; 9(3):. PubMed ID: 32726928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal Models of Type III Secretion System-Mediated Pathogenesis.
    Hotinger JA; May AE
    Pathogens; 2019 Nov; 8(4):. PubMed ID: 31766664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing Cyclic Peptomers as Broad-Spectrum Type III Secretion System Inhibitors in Gram-Negative Bacteria.
    Lam HN; Lau T; Lentz A; Sherry J; Cabrera-Cortez A; Hug K; Lalljie A; Engel J; Lokey RS; Auerbuch V
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0169020. PubMed ID: 33875435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Targets and Strategies for Inhibition of the Bacterial Type III Secretion System (T3SS); Inhibitors Directly Binding to T3SS Components.
    Hotinger JA; Pendergrass HA; May AE
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33669653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria.
    Keyser P; Elofsson M; Rosell S; Wolf-Watz H
    J Intern Med; 2008 Jul; 264(1):17-29. PubMed ID: 18393958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacterial adhesion and host cell factors leading to effector protein injection by type III secretion system.
    Bohn E; Sonnabend M; Klein K; Autenrieth IB
    Int J Med Microbiol; 2019 Jul; 309(5):344-350. PubMed ID: 31178419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic Cyclic Peptomers as Type III Secretion System Inhibitors.
    Lam H; Schwochert J; Lao Y; Lau T; Lloyd C; Luu J; Kooner O; Morgan J; Lokey S; Auerbuch V
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and biophysics of type III secretion in bacteria.
    Chatterjee S; Chaudhury S; McShan AC; Kaur K; De Guzman RN
    Biochemistry; 2013 Apr; 52(15):2508-17. PubMed ID: 23521714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-Molecule Inhibitors of the Type III Secretion System.
    Gu L; Zhou S; Zhu L; Liang C; Chen X
    Molecules; 2015 Sep; 20(9):17659-74. PubMed ID: 26404233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting bacterial pathogenesis by inhibiting virulence-associated Type III and Type IV secretion systems.
    Blasey N; Rehrmann D; Riebisch AK; Mühlen S
    Front Cell Infect Microbiol; 2022; 12():1065561. PubMed ID: 36704108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-Labeling Enzyme Tags for Analyses of Translocation of Type III Secretion System Effector Proteins.
    Göser V; Kommnick C; Liss V; Hensel M
    mBio; 2019 Jun; 10(3):. PubMed ID: 31239375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative Autogenous Control of the Master Type III Secretion System Regulator HrpL in Pseudomonas syringae.
    Waite C; Schumacher J; Jovanovic M; Bennett M; Buck M
    mBio; 2017 Jan; 8(1):. PubMed ID: 28119474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topological Analysis of the Type 3 Secretion System Translocon Pore Protein IpaC following Its Native Delivery to the Plasma Membrane during Infection.
    Russo BC; Duncan JK; Goldberg MB
    mBio; 2019 May; 10(3):. PubMed ID: 31138750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudomonas aeruginosa Magnesium Transporter MgtE Inhibits Type III Secretion System Gene Expression by Stimulating
    Chakravarty S; Melton CN; Bailin A; Yahr TL; Anderson GG
    J Bacteriol; 2017 Dec; 199(23):. PubMed ID: 28847924
    [No Abstract]   [Full Text] [Related]  

  • 15. Natural compound sanguinarine chloride targets the type III secretion system of
    Zhang Y; Liu Y; Wang T; Deng X; Chu X
    Biochem Biophys Rep; 2018 Jul; 14():149-154. PubMed ID: 29761161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bacterial type III secretion system as a target for developing new antibiotics.
    McShan AC; De Guzman RN
    Chem Biol Drug Des; 2015 Jan; 85(1):30-42. PubMed ID: 25521643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches targeting the type III secretion system to treat or prevent bacterial infections.
    Charro N; Mota LJ
    Expert Opin Drug Discov; 2015 Apr; 10(4):373-87. PubMed ID: 25727140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Type III secretion system of Gram-negative bacteria: a potential therapeutic target?
    Müller S; Feldman MF; Cornelis GR
    Expert Opin Ther Targets; 2001 Jun; 5(3):327-339. PubMed ID: 12540268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First multi-epitope subunit vaccine against extraintestinal pathogenic Escherichia coli delivered by a bacterial type-3 secretion system (T3SS).
    Wieser A; Magistro G; Nörenberg D; Hoffmann C; Schubert S
    Int J Med Microbiol; 2012 Jan; 302(1):10-8. PubMed ID: 22000741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yersinia type III effectors perturb host innate immune responses.
    Pha K; Navarro L
    World J Biol Chem; 2016 Feb; 7(1):1-13. PubMed ID: 26981193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.